TY - JOUR
T1 - Partially covered versus uncovered pyloro-duodenal stents for unresectable malignant gastric outlet obstruction
T2 - Randomized controlled study
AU - Teoh, Anthony Yuen Bun
AU - Lakhtakia, Sundeep
AU - Tan, Damien Meng Yew
AU - Crinò, Stefano Francesco
AU - Dhir, Vinay
AU - Kunda, Rastislav
AU - Ang, Tiing Leong
AU - Ho, Khek Yu
AU - Aerts, Maridi
AU - Aigindia, Sana
AU - Chan, Shannon Melissa
AU - Chiu, Philip Wai Yan
AU - Conti Bellocchi, Maria Cristina
AU - Messaoudi, Nouredin
AU - Ng, Stephen Ka Kei
AU - Yip, Hon Chi
AU - Gabbrielli, Armando
AU - Khor, Christopher Jen Lock
AU - Ramchandani, Mohan
AU - Ng, Enders Kwok Wai
N1 - Funding Information:
This study was fully supported by a grant from the Health and Medical Research Fund, Hong Kong Special Administrative Region, China (Project No. 04152766).
Publisher Copyright:
© 2023 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
PY - 2024/4
Y1 - 2024/4
N2 - Objectives: The aim of the current study was to compare the efficacy of partially covered duodenal stent (PCDS) vs. uncovered duodenal stent (UCDS) in patients suffering from unresectable primary malignant gastric outlet obstruction (GOO). Methods: This was a prospective international randomized controlled study conducted in 10 high-volume institutions. Consecutive patients suffering from malignant GOO were recruited. The primary outcome measurement was the reintervention rate. Secondary outcomes included technical and clinical success, 30-day adverse events, 30-day mortality, causes of stent dysfunction, and the duration of stent patency. Results: Between March 2017 and October 2020, 115 patients (59 PCDS, 56 UCDS) were recruited. The 1-year reintervention was not significantly different (PCDS vs. UDCS = 12/59, 20.3% vs. 14/56, 25%, P = 0.84). There was a trend to fewer patients with tumor ingrowth in the PCDS group (6/59 [10.2%]) vs. 13/56 [23.2%], P = 0.07). There were no significant differences in the technical success (100% vs. 100%, P = 1), clinical success (91.5% vs. 98.2%, P = 0.21), procedural time (21.5 [interquartile range [IQR] 17–30] vs. 20.0 [IQR 15–34.75], P = 0.62), hospital stay (4 [IQR 3–12] vs. 5 [IQR 3–8] days, P = 0.81), 30-day adverse events (18.6% vs. 14.3%, P = 0.62), or 30-day mortality (6.8% vs. 5.2%, P = 1.00). Conclusion: The use of PCDS was associated with a lower risk of tumor ingrowth but did not improve on reintervention rates or stent patency. Both kinds of stents could be used in this group of patients.
AB - Objectives: The aim of the current study was to compare the efficacy of partially covered duodenal stent (PCDS) vs. uncovered duodenal stent (UCDS) in patients suffering from unresectable primary malignant gastric outlet obstruction (GOO). Methods: This was a prospective international randomized controlled study conducted in 10 high-volume institutions. Consecutive patients suffering from malignant GOO were recruited. The primary outcome measurement was the reintervention rate. Secondary outcomes included technical and clinical success, 30-day adverse events, 30-day mortality, causes of stent dysfunction, and the duration of stent patency. Results: Between March 2017 and October 2020, 115 patients (59 PCDS, 56 UCDS) were recruited. The 1-year reintervention was not significantly different (PCDS vs. UDCS = 12/59, 20.3% vs. 14/56, 25%, P = 0.84). There was a trend to fewer patients with tumor ingrowth in the PCDS group (6/59 [10.2%]) vs. 13/56 [23.2%], P = 0.07). There were no significant differences in the technical success (100% vs. 100%, P = 1), clinical success (91.5% vs. 98.2%, P = 0.21), procedural time (21.5 [interquartile range [IQR] 17–30] vs. 20.0 [IQR 15–34.75], P = 0.62), hospital stay (4 [IQR 3–12] vs. 5 [IQR 3–8] days, P = 0.81), 30-day adverse events (18.6% vs. 14.3%, P = 0.62), or 30-day mortality (6.8% vs. 5.2%, P = 1.00). Conclusion: The use of PCDS was associated with a lower risk of tumor ingrowth but did not improve on reintervention rates or stent patency. Both kinds of stents could be used in this group of patients.
KW - malignant gastric outlet obstruction
KW - partially covered duodenal stent
KW - uncovered duodenal stent
UR - http://www.scopus.com/inward/record.url?scp=85169127736&partnerID=8YFLogxK
U2 - 10.1111/den.14650
DO - 10.1111/den.14650
M3 - Article
C2 - 37522554
AN - SCOPUS:85169127736
SN - 0915-5635
VL - 36
SP - 428
EP - 436
JO - Digestive Endoscopy
JF - Digestive Endoscopy
IS - 4
ER -